The table below shows Kymera Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$88.84M
-$79.15M
-$39.59M
-$43.97M
-$40.30M
-$22.82M
Capital expenditure
$434.00K
$467.00K
$7.40M
$4.01M
$482.00K
$164.00K
Investing cash flow
-$142.84M
$48.62M
-$330.61M
$24.58M
$25.86M
$44.32M
Dividends paid
-
-
-
KYMR operating cash flow (10-K history)
Kymera Therapeutics, Inc. reported operating cash flow of -$232.89M for fiscal year 2025. That is down 19.7% from -$194.50M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $17.91M (FY 2019) to -$232.89M. Figures come from the company's audited annual reports as filed with the SEC.
